Hope for hundreds of thousands with type 1 diabetes as major study reveals arthritis drug can suppress the condition
In a world-first clinical trial, researchers in Australia found that baricitinib can preserve the body's own insulin production. (Source: the Mail online | Health)
Source: the Mail online | Health - December 6, 2023 Category: Consumer Health News Source Type: news
Are Immune Therapies for Type 1 Diabetes Worthwhile? Are Immune Therapies for Type 1 Diabetes Worthwhile?
Recently published studies of two different immunologic agents show beta-cell preservation in people with newly diagnosed disease, but no differences in glycemic control and ongoing insulin requirement.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 6, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology Source Type: news
Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes
Carmot Therapeutics ’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche ’s in-house assetsLead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbiditiesUnder the terms of the agreement, Roche will pay a purchase price of USD 2.7 billion upfront and additional milestone payments of up to USD 400 millionBasel, 4 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger a...
Source: Roche Investor Update - December 4, 2023 Category: Pharmaceuticals Source Type: news
Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes
Carmot Therapeutics ’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with Roche ’s in-house assetsLead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist with best-in-class potential for the treatment of obesity and its comorbiditiesUnder the terms of the agreement, Roche will pay a purchase price of USD 2.7 billion upfront and additional milestone payments of up to USD 400 millionBasel, 4 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger a...
Source: Roche Media News - December 4, 2023 Category: Pharmaceuticals Source Type: news
Picture quiz: Toenail presentations
The Nursing in Practice ‘picture quizzes’ aim to test your knowledge through photo presentations of symptoms. Work your way through them to understand the key clinical problems faced by patients, and how to correctly identify them. Press ‘start’ below to begin the quiz.
A 45-year-old woman is concerned about this black line that has appeared under her big toenail. Can you reassure her about the cause?
Fungal nail infection
Melanoma
Subungual haematoma
Ingrowing toenail
A 23-year-old woman wants to know what you are going to do about her ‘manky toenail’ as it is summer and she feels she ...
Source: Nursing in Practice - November 23, 2023 Category: Nursing Authors: Mollie Fraser-Andrews Tags: Dermatology Quiz toenail Source Type: news
vTv Therapeutics regains compliance with Nasdaq after 1-for-40 reverse stock split
High Point's biopharmaceutical company vTv Therapeutics is back in good standing with Nasdaq after months of being in danger of being delisted. At its lowest point in the past year, the company's stock had traded for $0.35 per share. Find out just how big a jump the stock price took and if this means the company, which is developing an oral treatment for Type 1 diabetes, is truly in good financial standing. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 21, 2023 Category: Pharmaceuticals Authors: Lillian Johnson Source Type: news
Already-Available Drug Could Help Treat Type 1 Diabetes Already-Available Drug Could Help Treat Type 1 Diabetes
The ornithine decarboxylase inhibitor α-difluoromethylornithine, used to treat African sleeping sickness and unwanted hair growth, may also protect β cells of people with new-onset type 1 diabetes.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - November 20, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Who Has Type 1 Diabetes?
With Wednesday being World Diabetes Day, it's worth looking at which countries have the highest number of people with the disease. Wilford Brimley According to Anna Fleck of Statista, citing data from the NHS, there are two main types of diabetes: Diabetes type 1 is…#worlddiabetesday #wilfordbrimley #annafleck #nhs #unitedkingdom (Source: Reuters: Health)
Source: Reuters: Health - November 18, 2023 Category: Consumer Health News Source Type: news
Diabetes screening for 20,000 adults across the UK
A study that will screen 20,000 UK adults for type 1 diabetes was launched this week by the University of Bristol to coincide with World Diabetes Day. The study, known as the Type 1 Diabetes Risk in Adults (TQDRA), aims to recruit 20,000 adults between the ages of 18 and 70 from the general population... Read moreThe post Diabetes screening for 20,000 adults across the UK appeared first on Nursing in Practice. (Source: Nursing in Practice)
Source: Nursing in Practice - November 16, 2023 Category: Nursing Authors: Carolyn Scott Tags: Diabetes type 1 diabetes Source Type: news
vTv Therapeutics loses $6.7M in Q3, could lose spot on NASDAQ index
With its Nasdaq listing hanging in the balance, vTv Therapeutics says its board has still not set a date or ratio for a reverse stock split. The High Point biopharmaceutical company's stock price has been consistently under Nasdaq's $1 minimum and it hopes that a reverse stock split will help it avoid being delisted. Find out more about its rocky financials and how it could affect the development of its Type 1 diabetes treatment. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 15, 2023 Category: Biotechnology Authors: Lillian Johnson Source Type: news
World-first study to screen 20,000 UK adults for type 1 diabetes
A world-first research programme led by the University of Bristol that will identify adults at high risk of developing type 1 diabetes opens for recruitment today. Launching on World Diabetes Day [14 Nov 2023], the Type 1 Diabetes Risk in Adults (T1DRA) study aims to recruit 20,000 adults, aged between 18 and 70, from the general population to assess their risk. (Source: University of Bristol news)
Source: University of Bristol news - November 14, 2023 Category: Universities & Medical Training Tags: Research, Health; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School; Press Release Source Type: news
Nick Jonas joins national campaign to'See The Signs' of diabetes
Singer Nick Jonas has teamed up with Beyond Type 1 to announce a new national campaign called " See The Signs, " to help people identify the symptoms of diabetes, which if undiagnosed could lead to complications or death. (Source: Health News - UPI.com)
Source: Health News - UPI.com - November 14, 2023 Category: Consumer Health News Source Type: news
Get an 'artificial pancreas' on the NHS: 150,000 type 1 diabetes sufferers are set to get gadget hailed as the 'biggest breakthrough since discovery of insulin'
National Institute of Health and Care Excellence (NICE) chiefs recommend people in England and Wales can get a hybrid closed loop system if their type 1 diabetes is not adequately controlled. (Source: the Mail online | Health)
Source: the Mail online | Health - November 7, 2023 Category: Consumer Health News Source Type: news
NICE recommends 'artificial pancreas' tech for patients with type 1 diabetes
Just over 150,000 adults and children with type 1 diabetes in England and Wales could be offered hybrid closed loop systems on the NHS, following new draft NICE guidance. (Source: GP Online News)
Source: GP Online News - November 7, 2023 Category: Primary Care Tags: Clinical News Source Type: news
November is National Diabetes Month
Whether you’re a diabetes patient, a friend or family member of someone with diabetes, a health professional, librarian, or just curious to learn more about diabetes, we hope you’ll find the following list of resources useful. It includes information about diabetes, tools for self management, tips for preventing complications, and more.
Medline Plus: Diabetes
Medline Plus has information on type 1 diabetes, type 2 diabetes, prediabetes, and gestational diabetes. Find information about symptoms, tests, possible complications, prevention, diet, medicines, treatments, genetics, statistics, and more.
...
Source: The Cornflower - November 6, 2023 Category: Databases & Libraries Authors: Nora Barnett Tags: Blog Source Type: news
